Form 4: FibroBiologics Chief Scientific Officer Hamid Khoja Reports Stock Transaction
SEC Form 4 Filing
Hamid Khoja, Chief Scientific Officer of FibroBiologics, Inc. (FBLG), reported the acquisition and disposal of common stock on August 12, 2024.
Summary
- On August 12, 2024, Hamid Khoja, the Chief Scientific Officer of FibroBiologics, Inc., engaged in a transaction involving the company's common stock.
- Khoja acquired 10,000 shares of common stock at a price of $1.9 per share.
- Khoja disposed of 11,250 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of a stock transaction by a company insider. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transaction may have a minor impact on shareholders' perception of the company, depending on how they interpret the insider's trading activity.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of stock transaction: acquisition of 10,000 shares and disposal of 11,250 shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.